Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has issued an update.
Race Oncology Ltd has announced the initiation of new clinical trials for their drug RC220 in treating Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC). The trials aim to leverage the unique molecular mechanism of action of (E,E)-bisantrene to address treatment resistance in NSCLC and establish a cost-effective pathway to regulatory approval for AML. These developments are expected to enhance Race Oncology’s market positioning by potentially providing new treatment options in significant cancer markets. The company is well-funded to support these initiatives, with existing resources expected to cover all trials and programs until mid-2027.
More about Race Oncology Ltd.
Race Oncology Ltd is a company operating in the biotechnology industry, focusing on developing cancer therapies. Their primary products include RC220, which is used in clinical trials for treating Acute Myeloid Leukemia and Non-Small Cell Lung Cancer. The company is known for its innovative approaches to addressing unmet medical needs in cancer treatment.
Average Trading Volume: 521,451
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$581.1M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.